Healthcare Policy

Healthcare Policy 15(4) May 2020 : 26-34.doi:10.12927/hcpol.2020.26227
Discussion and Debate

Health Canada’s Proposal to Accelerate New Drug Reviews

Joel Lexchin

Abstract

Health Canada is proposing to update its accelerated review pathways to get important new drugs into the market more quickly. To date, the two pathways that Health Canada uses have not demonstrated that they can identify therapeutically valuable new drugs. Drugs approved under the two pathways also have a greater likelihood of acquiring a serious safety warning post-marketing compared with drugs approved through the standard review pathway. The new proposals from Health Canada will not go far in rectifying this situation, and major changes are needed. Health Canada needs to present evidence that the changes it is proposing will actually allow these pathways to fulfill the set objectives and support health benefits for Canadians.

 

Comments

Be the first to comment on this!

Note: Please enter a display name. Your email address will not be publically displayed